<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201222049802N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-15</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>Oral nystatin prophylaxis to prevent of  candida colonization in premature infant with weigth less than 1500 gram  in Neonatal Intensive care Unit</public_title>
      <acronym></acronym>
      <scientific_title>Oral nystatin prophylaxis to prevent of  candida colonization in premature infant with weigth less than 1500 gram  in Neonatal Intensive care Unit</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>106</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54207</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: Infants are randomly divided into one of two groups, the nystatin group and the control group. Infants in both groups are similar in age, sex, gestational age, weight, and other anthropometric findings. Infants in the nystatin group receive 100,000 UI / ml, 0.5 ml intraorally and 0.5 ml via the urogastric tube three times a day from the nystatin oral suspension of Emad Darman Pars Company. The control group did not receive antifungal prophylaxis, Randomization description: Random sequence through a table of random numbers.</study_design>
      <phase>3</phase>
      <hc_freetext>candida colonization.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: Infants born in Ayatollah Mousavi Hospital in Zanjan or admitted from other hospitals in the province who are in the first 72 hours of life and are admitted to the neonatal intensive care unit and have a gestational age  less than 32w or birth weight  less than 1500gr, From the oral suspension of nystatin of Emad Darman Pars Company, they receive 100,000 UI / ml, 1ml (0.5 ml into the oral cavity and 0.5 ml through the urogastric tube) three times a day. The mouth and rectum are prepared for smear and fungal culture and sent to the laboratory of Mousavi Hospital in Zanjan for analysis. Intervention 2: Control group: Control group: Intervention group: Infants born in Ayatollah Mousavi Hospital in Zanjan or admitted from other hospitals in the province who are in the first 72 hours of life and are hospitalized in the neonatal intensive care unit and have a gestational age less than 32w or birth weight less than 1500gr, the control group does not receive antifungal prophylaxis. After a week, a swab is prepared from the oral mucosa and rectum for smear and culture of the fungus and sent to the laboratory of Mousavi Hospital in Zanjan for analysis.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The release schedule will be announced soon.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Asghar Marzban</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ayatollah Mousavi Hospital, Gavazang Road, Above Shahid Sabouti Boulevard, zanjan, iran.</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4513956183</zip>
        <telephone>+98 24 3342 0651</telephone>
        <email>Drmarzban@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Asghar Marzban</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ayatollah Mousavi Hospital, Gavazang Road, Above Shahid Sabouti Boulevard, zanjan, iran.</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4513956183</zip>
        <telephone>+98 24 3342 0651</telephone>
        <email>Drmarzban@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>infants born in the first 72 hours of life
birth weight less than 1500gram
gestational age less than 32 weeks
who are hospitalized in the neonatal intensive care unit</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>3 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>severe abnormalities
chromosomal abnormalities
severe sepsis
Congenital heart disease
Intraventricular hemorrage
disseminated  intravascular coagulation
Thrush
congenital disorders requiring surgery
Fungal infections proven by blood or urine culture require treatment with appropriate antifungal drugs such as amphotericinCommunity Verified icon
Parents' dissatisfaction with the infant's participation in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P37.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Neonatal candidiasis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: Infants born in Ayatollah Mousavi Hospital in Zanjan or admitted from other hospitals in the province who are in the first 72 hours of life and are admitted to the neonatal intensive care unit and have a gestational age  less than 32w or birth weight  less than 1500gr, From the oral suspension of nystatin of Emad Darman Pars Company, they receive 100,000 UI / ml, 1ml (0.5 ml into the oral cavity and 0.5 ml through the urogastric tube) three times a day. The mouth and rectum are prepared for smear and fungal culture and sent to the laboratory of Mousavi Hospital in Zanjan for analysis.</i_keyword>
      <i_keyword>Control group: Control group: Intervention group: Infants born in Ayatollah Mousavi Hospital in Zanjan or admitted from other hospitals in the province who are in the first 72 hours of life and are hospitalized in the neonatal intensive care unit and have a gestational age less than 32w or birth weight less than 1500gr, the control group does not receive antifungal prophylaxis. After a week, a swab is prepared from the oral mucosa and rectum for smear and culture of the fungus and sent to the laboratory of Mousavi Hospital in Zanjan for analysis.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Gestetional age. Timepoint: Week. Method of measurement: The number of weeks that have elapsed since the last menstrual period.</prim_outcome>
      <prim_outcome>Birth weight. Timepoint: Birth. Method of measurement: Weighing the baby.</prim_outcome>
      <prim_outcome>Type of delivery(Natural vaginal delivery or cesarean section). Timepoint: at birth. Method of measurement: Get a history and file.</prim_outcome>
      <prim_outcome>Premature rupture of the membrane. Timepoint: rupture of the membrane&gt;18houres. Method of measurement: Get a history and file.</prim_outcome>
      <prim_outcome>Use of broad-spectrum antibiotics (third-generation cephalosporins and carbapenems). Timepoint: One week after birth. Method of measurement: Get a history and file.</prim_outcome>
      <prim_outcome>Receive invasive  respiratory ventilation. Timepoint: One week after birth. Method of measurement: Get a history and file.</prim_outcome>
      <prim_outcome>Oral culture and smear for fungi. Timepoint: one week after birth. Method of measurement: laboratory report.</prim_outcome>
      <prim_outcome>Rectal culture and smear for fungi. Timepoint: One week after birth. Method of measurement: laboratory report.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University Of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-16</approval_date>
        <contact_name>Ethics committee of Zanjan University of Medical Sciences</contact_name>
        <contact_address>Ayatollah Mousavi Hospital, Above Shahid Sabouti Boulevard, Gavazang Road, Zanjan, Iran. Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
